Home

Sites

Company Introduction

Contact Us

Project&Products

26 Oct, 2022

new Industrial platform

Virtue Took on National Standard Substance Calibration Projects

diagnostic systems

Creating a

1 Apr，2023

Labtest Debuted Its Latest CLIA Solution at the 2023 CBPC/ML

Creating a new Industrial platform focused on enabling innovative next generation in vitro diagnostic systems

Aug, 2020

27 Jul, 2023

Virtue Announced Acquisition of Labtest Diagnostics in Brazil

3 Aug, 2023

Virtue Showcased Clinical MS Technology at 2022 CACLP

Virtue and Labtest Made an Impressive Debut at the 2023 AACC

18 Aug, 2023

Virtue Honored with the 2023 Best IVD Enterprise Award

in vitro

8 Sep, 2023

next generation

Virtue Diagnostics closes $100 million Series B Funding

Virtue Showcased QSight 420MD at the 2023 NCLM

focused on enabling innovative

1 Sep, 2022

al_PhysicalPresence

About / 01

al_CompanyVideo

Our Vision

al_Focus

About / 02

About / 03

Focus

al_CollaborativeRD

Virtue Diagnostics is an innovative IVD company focused on infectious disease, cancer, and chronic diseases. Our goal is to utilize our diverse technology platforms to provide clinical solutions for patients at all disease stages including early screening, initial diagnosis, treatment monitoring and minimal residual disease management.

About / 04

Create a leading innovative global diagnostic company by leveraging diverse technology platforms through internal development and external collaboration.

al_TechnologyPlatforms

Our Mission

Technology Platforms

Virtue Suzhou Site Grand Openning

Physical Presence

VIRTUEDX Company Video

al_WhoWeAre

Virtue Diagnostics has built a team of experienced leaders around specific technology platforms coupled with automated workstation capabilities for chemiluminescence, clinical mass spectrometry, multi-label pathology, single cell technology and other molecular biology technologies.

al_Mission

Virtue Diagnostics’ physical presence is split between Singapore, Suzhou and Beijing China. Our R&D is headquartered in Singapore, manufacturing in Suzhou, and our CRO in Beijing. In 2020, we opened a highly advanced, 1000 m² R&D center, that was designed to incorporate diverse technical capabilities with a strong desire to foster collaborative development. Our new 6000 m² diagnostic instrument and reagent manufacturing site at Biobay in the Suzhou Industrial Park, is open and has begun instrument manufacturing. Our 500 m² CRO in Beijing is focused cancer detection using next generation Pathology platforms.

Collaborative R&D

Virtue Diagnostics has adopted a new collaborative model, which establishes a complete industrial chain from innovative research and development to clinical trials, clinical applications, and large-scale industrialization. It serves the world's advanced diagnostic technologies and provides solutions to China and other emerging markets.

Accelerate clinical diagnostics innovation for a healthier world

Who We Are 

News

Country / Region

Products

Investors

Careers

al_Hematology

Thoughtput Photometric 360T/H and ISE 180T/H Sample Capacity 100 Reagent Position 100

Dual Source HSID (Hot Source Induced Desolvation) Laminar Flow Ion Guide UniField Detector

As in mass spectrometry, the equipment for mIHC was designed for research labs. This equipment is exceedingly expensive and has not been designed for hundreds or thousands of clinical samples. Based on our partnership with a leading mIHC service laboratory in China, we will develop a vastly lower cost IHC multiplex cell analysis platforms specifically designed for the clinical market. We also see exceptional opportunity to bring solutions for single cell analysis, digital/next generation pathology for treatment involving checkpoint inhibitors and immune modulators.

VERCENTRA CS-3000

Audmax 360

QSight 420MD

Advances in genomics and proteomics has enabled researchers to uncover the molecular events that are the underlying basis for developing a disease. Often a combination of genetic changes either through spontaneous mutations or inheritance, lead to this disease state. Identifying and understanding these molecular changes has driven clinicians and researchers to diagnose and treat disease in a novel way. Pathology, the discipline of physical identification of disease within tissue or cells, has now become the center point to ascertain exactly what is problem and if or how it may be treated. Visualization of excised tissue or isolated circulating tumor cells involves multiplex immunohistochemistry or mIHC. mIHC, involves using highly specific stains to identify molecular markers that are disease specific. Gone are the days of labeling cancer based on the organ or site of identification. Today, the underlying genetic changes that leads to the disease is identified and appropriate treatments are recommended.

Biochemistry

Multiplex Pathology

ObjAreasA

al_Others

Thoughtput 120T/H Sample Capacity 24  Reagent Position 15

Thoughtput Photometric 240T/H and ISE 240T/H Sample Capacity 80 Reagent Position 80

ObjAreasB

Category 3-Part Thoughtput 40 T/H Parameters 19

Audmax 240

VERCENTRA CS-1500

ObjAreasC

Chemiluminescence

Aud H3

Blood cell analysis platforms, based on automation, are devices that can rapidly and accurately classify and count blood samples, enhancing laboratory efficiency and reducing human errors. They can simultaneously measure multiple blood cell parameters, such as white blood cell count, red blood cell count, hemoglobin concentration, platelet count, etc., providing comprehensive blood analysis information. Blood cell analysis platforms can be categorized into 3-classification and 5-classification based on whether they further classify white blood cells into lymphocytes, neutrophils, and monocytes.

Hematology

Clinical Mass Spectrometry

Thoughtput Photometric 800T/H and ISE 460T/H Sample Capacity 140 Reagent Position 134

Thoughtput Photometric 180T/H and ISE 360T/H Sample Capacity 40 Reagent Position 80

Audmax 800

Although LC-MS has been used for newborn screening globally for many years, its application in specialized diagnostics is subject to higher restrictions. Automated operation, user-friendly software, and pre-packaged reagent kits are crucial for the further promotion of LC-MS. With the maturation and commercialization of the technology, improvements in these aspects will enhance the usability and reliability of the equipment, facilitating broader clinical applications and making it an essential tool in clinical diagnostics.

al_ClinicalMass Spectrometry

Category 5-Part Thoughtput 60 T/H Parameters 25+4 research ones

Audmax 180 Evolution

Go to Panovue

Chemiluminescence immunoassay technology is classified into three major platforms based on different luminescence principles: enzyme-linked chemiluminescence, direct chemiluminescence, and electrochemiluminescence. Among them, direct chemiluminescence using acridinium esters as the luminescent label does not require enzymatic catalysis. The system is more stable, and the luminescence in the direct chemiluminescence system is rapid, resulting in shorter time to obtain results. Moreover, acridinium esters, as the luminescent marker, offer significant advantages compared to luminol-based systems, including better control over labeling, lower background signal levels, improved signal-to-noise ratio, absence of intrinsic luminescence, and stable detection results.

Aud H5

Others

Thoughtput 800T/H Sample Capacity 180 Reagent Position 200

Thoughtput Photometric 600T/H and ISE 400T/H Sample Capacity 115 Reagent Position 112

al_Chemiluminescence

VERCENTRA CH-800

Audmax 600

Category 5-Part with autoload Thoughtput 60 T/H Parameters 27

al_Biochemistry

Aud H5AL

ObjAreasD

Liquid chromatography-tandem mass spectrometry (LC-MS) is a relatively new technology in the field of clinical diagnostics. Mass spectrometry provides unparalleled sensitivity and specificity for the analysis of metabolites, particularly in the detection of structurally similar small molecules such as vitamins, steroids, and hormones, where it offers significant advantages.

ObjAreasE

Thoughtput Photometric 400T/H and ISE 400T/H Sample Capacity 115 Reagent Position 67 on R1 and 45 on R2 disc

Thoughtput 400T/H Sample Capacity 96 Reagent Position 72

Audmax 400

Category 3-Part Thoughtput 60 T/H Parameters 24

VERCENTRA CH-400

al_Products

VERCENTRA HA-30

Biochemical analysis is one of the important analysis platforms frequently used in clinical laboratory testing. It involves analyzing blood or other body fluids to measure various biochemical indicators, such as transaminases, hemoglobin, albumin, total protein, cholesterol, creatinine, glucose, inorganic phosphorus, amylase, calcium, and more. A fully automated biochemical analyzer, as the name suggests, automates the steps of sampling, reagent addition, mixing, incubation, detection, result calculation and display, as well as cleaning during the analysis process. It can completely mimic and replace manual operations. Fully automated biochemical analyzers are sensitive, accurate, and fast, not only improving work efficiency but also reducing subjective errors and enhancing the quality of laboratory testing.

Thoughtput 240T/H Sample Capacity 96  Reagent Position 24

Investor

[if gte mso 9]> Normal 0 7.8 磅 0 2 false false false EN-US ZH-CN AR-SA